Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
Europe
EU
Celyad Oncology SA (CYAD)
Celyad Oncology SA (CYAD) News

CYAD

Celyad Oncology (CYAD)

Celyad Oncology SA

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:EU:CYAD

<< Previous 1 2 3 4 5 Next >>

Date	Time	Source	Headline	Symbol	Company
08/25/2016	1:08AM	GlobeNewswire Inc.	Celyad Reports First Half 2016 Financial Results and Operational Progress	EU:CYAD	Celyad Oncology SA
07/14/2016	3:21AM	Cercle Finance	Celyad: la phase I se poursuit sur NKR-2.	EU:CYAD	Celyad Oncology SA
07/14/2016	1:04AM	GlobeNewswire Inc.	CELYAD S.A.: Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase ...	EU:CYAD	Celyad Oncology SA
07/11/2016	5:52AM	Cercle Finance	Celyad: accord de licence avec Ono Pharmaceutical.	EU:CYAD	Celyad Oncology SA
07/11/2016	4:07AM	GlobeNewswire Inc.	CELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immuno...	EU:CYAD	Celyad Oncology SA
06/28/2016	8:02AM	Cercle Finance	Celyad: une 'tendance positive' lors de tests de phase III.	EU:CYAD	Celyad Oncology SA
06/28/2016	6:17AM	GlobeNewswire Inc.	CELYAD S.A.: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy	EU:CYAD	Celyad Oncology SA
06/14/2016	3:46AM	Cercle Finance	Celyad: l'équipe de Boston renforcée.	EU:CYAD	Celyad Oncology SA
06/06/2016	8:53AM	Cercle Finance	Celyad: nomme un vice-président R&D.	EU:CYAD	Celyad Oncology SA
05/26/2016	6:22AM	Cercle Finance	Celyad: l'essai de phase I/IIa se poursuit comme prévu.	EU:CYAD	Celyad Oncology SA
03/09/2016	7:46PM	GlobeNewswire Inc.	Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells	EU:CYAD	Celyad Oncology SA
03/09/2016	7:46PM	GlobeNewswire Inc.	Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells	EU:CYAD	Celyad Oncology SA
03/09/2016	7:46PM	GlobeNewswire Inc.	Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Pati...	EU:CYAD	Celyad Oncology SA
03/09/2016	7:46PM	GlobeNewswire Inc.	Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Pati...	EU:CYAD	Celyad Oncology SA
02/08/2016	1:00AM	GlobeNewswire Inc.	Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination...	EU:CYAD	Celyad Oncology SA
02/08/2016	1:00AM	GlobeNewswire Inc.	Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination...	EU:CYAD	Celyad Oncology SA
02/03/2016	1:00AM	GlobeNewswire Inc.	Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs	EU:CYAD	Celyad Oncology SA
02/03/2016	1:00AM	GlobeNewswire Inc.	Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs	EU:CYAD	Celyad Oncology SA
01/20/2016	1:00AM	GlobeNewswire Inc.	Celyad Announces 2016 Financial Calendar	EU:CYAD	Celyad Oncology SA
01/20/2016	1:00AM	GlobeNewswire Inc.	Celyad Announces 2016 Financial Calendar	EU:CYAD	Celyad Oncology SA
01/05/2016	1:00AM	GlobeNewswire Inc.	Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial	EU:CYAD	Celyad Oncology SA
01/05/2016	1:00AM	GlobeNewswire Inc.	Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial	EU:CYAD	Celyad Oncology SA
12/23/2015	1:00AM	GlobeNewswire Inc.	Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference	EU:CYAD	Celyad Oncology SA
12/23/2015	1:00AM	GlobeNewswire Inc.	Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference	EU:CYAD	Celyad Oncology SA
12/21/2015	1:00AM	GlobeNewswire Inc.	Celyad Receives Clearance From the US FDA on Its CHART-2 Phase III IND	EU:CYAD	Celyad Oncology SA
12/21/2015	1:00AM	GlobeNewswire Inc.	Celyad Receives Clearance From the US FDA on Its CHART-2 Phase III IND	EU:CYAD	Celyad Oncology SA
12/16/2015	1:00AM	GlobeNewswire Inc.	Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure	EU:CYAD	Celyad Oncology SA
12/16/2015	1:00AM	GlobeNewswire Inc.	Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure	EU:CYAD	Celyad Oncology SA
12/01/2015	1:00AM	GlobeNewswire Inc.	Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial	EU:CYAD	Celyad Oncology SA
12/01/2015	1:00AM	GlobeNewswire Inc.	Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial	EU:CYAD	Celyad Oncology SA

Showing the most relevant articles for your search:EU:CYAD

<< Previous 1 2 3 4 5 Next >>

New Momentum (PK)

Ocean Power Technologies

1812 Brewing (PK)

Ubiquitech Software (PK)

Net Savings Link (PK)

Voip Pal Com (QB)

FuelCell Energy

RespireRx Pharmaceuticals (PK)

Digital Brand Media and ... (PK)

Enzolytics (PK)

Virexit Technologies (PK)

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions